Tianjin Pharmaceuticals Warns of Up to 68% Plunge in H1 Profit
MT Newswires Live
Jul 14
Tianjin Pharmaceuticals Da Ren Tang's (SGX:T14) expects first-half net profit attributable to shareholders to slump 66% to 68% year on year to between 620 million yuan and 660 million yuan.
The company attributed the sharp drop to the absence of a 1.31 billion yuan after-tax one-off gain recorded in the first half of 2025 from the disposal of its remaining 12% stake in Tianjin TSKF Pharmaceutical.
Excluding non-recurring items, the company expects first-half net profit to increase 2% to 9% to between 610 million yuan and 650 million yuan,it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.